- Home
- BLTE vs CALX Comparison
BLTE vs CALX Comparison
Compare BLTE & CALX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BLTE
- CALX
- Stock Information
- Founded
- BLTE 2018
- CALX 1999
- Country
- BLTE United States
- CALX United States
- Employees
- BLTE N/A
- CALX 1760
- Industry
- BLTE Biotechnology: Pharmaceutical Preparations
- CALX Telecommunications Equipment
- Sector
- BLTE Health Care
- CALX Consumer Discretionary
- Exchange
- BLTE Nasdaq
- CALX Nasdaq
- Market Cap
- BLTE 2.1B
- CALX 2.1B
- IPO Year
- BLTE 2022
- CALX 2010
- Fundamental
- Price
- BLTE $82.46
- CALX $32.13
- Analyst Decision
- BLTE Strong Buy
- CALX Strong Buy
- Analyst Count
- BLTE 4
- CALX 6
- Target Price
- BLTE $89.00
- CALX $42.50
- AVG Volume (30 Days)
- BLTE 107.6K
- CALX 1.1M
- Earning Date
- BLTE 11-12-2024
- CALX 10-28-2024
- Dividend Yield
- BLTE N/A
- CALX N/A
- EPS Growth
- BLTE N/A
- CALX N/A
- EPS
- BLTE N/A
- CALX N/A
- Revenue
- BLTE N/A
- CALX $890,128,000.00
- Revenue This Year
- BLTE N/A
- CALX N/A
- Revenue Next Year
- BLTE N/A
- CALX $3.13
- P/E Ratio
- BLTE N/A
- CALX N/A
- Revenue Growth
- BLTE N/A
- CALX N/A
- 52 Week Low
- BLTE $31.01
- CALX $26.76
- 52 Week High
- BLTE $86.53
- CALX $45.15
- Technical
- Relative Strength Index (RSI)
- BLTE 72.06
- CALX 43.40
- Support Level
- BLTE $80.00
- CALX $28.70
- Resistance Level
- BLTE $84.50
- CALX $32.43
- Average True Range (ATR)
- BLTE 4.46
- CALX 1.84
- MACD
- BLTE -0.22
- CALX -0.17
- Stochastic Oscillator
- BLTE 83.18
- CALX 36.61
About BLTE Belite Bio Inc
Belite Bio Inc is a clinical-stage biopharmaceutical drug development company focused on novel therapeutics targeting untreatable eye diseases involving retinal degeneration such as atrophic age-related macular degeneration and autosomal recessive Stargardt disease or STGD1, both of which progressively lead to permanent blindness, and metabolic diseases such as non-alcoholic fatty liver disease, or NAFLD, nonalcoholic steatohepatitis, or NASH, type 2 diabetes, or T2D, and gout.
About CALX Calix Inc
Calix Inc develops, market and sell Calix cloud, systems and software platforms to enable service providers of all types and sizes to innovate and transform. The company's customers utilize the real-time data and insights from Calix platforms to simplify their business and deliver experiences that excite their subscribers. The resulting growth in subscriber acquisition, loyalty and revenue creates more value for their businesses and communities. The Company's revenue is principally derived in the United States and it also has its presence in Middle East & Africa, Europe, Asia Pacific and other markets.